The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases, reviewing issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
HowellA., DeFriendD., RobertsonJ.Response to a specific antioestrogen (IC 182780) in tamoxifen-resistant breast cancer. Lancet.1995; 345: 29–30.
2.
HowellA., RobertsonJ.F., Quaresma AlbanoJ.Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol.2002; 20(16): 3396–403.
3.
OsborneC.K., PippenJ., JonesS.E.Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant vs anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol.2002; 20(16): 3386–95.
4.
SouglakosJ., MavroudisD., KakolyrisS.Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial. J Clin Oncol.2002; 20(11): 2651–7.
5.
AndreT., LouvetC., RaymondE.Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOL-FOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol.1998; 9(11): 1251–3.
6.
de GramontA., FigerA., SeymourM.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol.2000; 18(16): 2938–47.
7.
de GramontA., VignoudJ., TournigandC.Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer.1997; 33(2): 214–19.
8.
ComellaP., CasarettiR., CrucittaE.Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil IV bolus: A salvage regimen for colorectal cancer patients. Br J Cancer.2002; 86(12): 1871–5.
9.
KimK., NamE., LeeN.S.Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer. Am J Clin Oncol.2002; 25(4): 354–7.
10.
DelalogeS., LaademA., TaammaA.Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am J Clin Oncol.2000; 23(6): 569–74.
11.
DierasV., BougnouxP., PetitT.Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients. Ann Oncol.2002; 13(2): 258–66.
12.
MissetJ.L., VenninP., CholletP.H.Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients. Ann Oncol.2001; 12(10): 1411–5.
13.
LiuJ., KrautE., BenderJ.Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemother Pharmacol.2002; 49(5): 367–74.
14.
LouvetC., AndreT., LledoG.Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study. J Clin Oncol.2002; 20(6): 1512–8.
15.
KollmannsbergerC., RickO., DerigsH.G.Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol.2002; 20(8): 2031–7.
16.
MonnetI., deC.H., SoulieP.Oxaliplatin plus vinorelbine in advanced nonsmall-cell lung cancer: Final results of a multicenter phase II study. Ann Oncol2002; 13(1): 103–7.
17.
ZelekL., CottuP., Tubiana-HulinM.Phase II study of oxaliplatin and fluorouracil in taxane-and anthracycline-pretreated breast cancer patients. J Clin Oncol.2002; 20(10): 2551–8.
18.
GarufiC., NisticoC., BrienzaS.Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study. Ann Oncol.2001; 12(2): 179–82.
19.
BundredN., HowellA.Fulvestrant (Faslodex): Current status in the therapy of breast cancer. Expert Rev Anticancer Ther.2002; 2(2): 151–60
WardleyA.M.Fulvestrant: A review of its development, preclinical and clinical data. Int J Clin Pract.2002; 56(4): 305–9.
22.
RobertsonJ.F.ICI 182,780 (fulvestrant) — the first oestrogen receptor down-regulator — current clinical data. Br J Cancer.2001; 85(suppl 2): 11–4.
23.
PelleyR.J.Oxaliplatin: A new agent for colorectal cancer. Curr Oncol Rep.2001; 3(2): 147–55.
24.
CassidyJ.Review of oxaliplatin: An active platinum agent in colorectal cancer. Int J Clin Pract.2000; 54(6): 399–402.
25.
CulyC.R., ClemettD., WisemanL.R.Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs.2000; 60(4): 895–924.
